
TP53 mutations occurred in 3% of myeloproliferative neoplasms (MPNs) but 10% of myelofibrosis or blast-phase cohorts in a review of 11 cohort studies.
The American Journal of Managed Care
about 26 years ago
Accrediting Organizations and Quality Improvementabout 26 years ago
Diagnosis of Skin Disease by Nondermatologists





